Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHSR-1a), the same pathway the hormone ghrelin uses to trigger growth hormone release from the pituitary. It’s frequently discussed alongside CJC-1295 as a “GH support” pairing. It’s also one of the more selective molecules in this category — but selectivity in mechanism isn’t the same as a deep human evidence base, and it’s worth separating the two.

What it is

Ipamorelin belongs to a class of drugs called growth hormone secretagogues. Compared with earlier secretagogues, it’s described as more selective for growth hormone release, with less effect on cortisol and prolactin in the studies that have measured those markers — a mechanistic advantage that shows up consistently in the pharmacology literature.

What the evidence shows — and where the gaps are

• The direct human data is limited to a handful of small studies. A pharmacokinetic-pharmacodynamic study in healthy male volunteers (dose-escalation design, eight subjects per dose level) established that ipamorelin reliably stimulates GH release across a range of infusion rates, with predictable dose-response behavior. That confirms the mechanism in humans but says nothing about longer-term use or the outcomes it’s discussed for.
• The most rigorous published human trial tested a different question entirely. A Phase II randomized controlled trial (n=87) evaluated ipamorelin for postoperative ileus — recovery of bowel function after abdominal surgery — not for anti-aging, body composition, or recovery in healthy adults. It’s real controlled human data, but it doesn’t transfer to the uses most commonly discussed in wellness contexts.
• The bulk of the evidence base is preclinical. Ipamorelin has more than three decades of animal and in-vitro research behind it and is well-characterized pharmacologically, but published controlled human trials for the specific goals people bring to providers — body composition, recovery, longevity — do not exist.
• There is no FDA-approved ipamorelin product. No finished-drug version of ipamorelin, alone or combined with CJC-1295, has completed FDA review for any indication.

Current regulatory status

Ipamorelin is not an FDA-approved drug. On October 29, 2024 the PCAC voted 0-12 (1 abstention) against adding ipamorelin to the 503A Bulks List, and as of FDA’s April 2026 update ipamorelin acetate remains on the Category 2 list for 503B outsourcing facilities. It was not part of the July 2026 PCAC review, so that review does not change its status. For the current, up-to-date status across peptides, see the live legal status tracker.

What people discuss with providers

Conversations with licensed providers about ipamorelin typically focus on what the mechanistic and pharmacokinetic data does and doesn’t establish, how thin the controlled human evidence is for the outcomes it’s actually discussed for, and what legal access looks like given its current compounding status. This is general education, not a recommendation, and isn’t a substitute for an individualized medical evaluation.

Sources

• Raun et al. — “Ipamorelin, the first selective growth hormone secretagogue,” Eur J Endocrinol, PubMed
• Beck et al. — Ipamorelin in a rodent model of postoperative ileus, PubMed
• NCBI PMC — “Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis”

This article is educational and is not medical advice. Talk to a licensed provider before making any health decision.

← All articles